Filtered By:
Drug: Empagliflozin
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Integrating cardioprotective glucose-lowering medications into clinical practice
Patients with type 2 diabetes suffer from both microvascular and macrovascular complications. Optimal glycemic control is well known to reduce the microvascular complications of retinopathy, nephropathy, and neuropathy. However, despite having multiple classes of antidiabetes medications, we have not been able to favorably affect the cardiovascular (CV) complications of diabetes, which cause considerable morbidity and premature CV mortality in patients with diabetes. The recent publication of the EMPA-REG Outcome and the LEADER studies demonstrating favorable CV outcomes with empagliflozin and liraglutide have led to a dec...
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Sodium-glucose cotransporter 2 inhibitors and ischemic stroke.
CONCLUSION: Despite the multiple pleiotropic effects of SGLT-2 inhibitors, these agents do not appear to affect stroke risk. Ongoing large trials with longer follow-up will evaluate whether the pleiotropic effects of this class will translate into benefits in ischemic stroke prevention.
PMID: 29412119 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
The kidney and cardiovascular outcome trials
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) in nearly one in five patients, with increasing age, blood pressure, obesity, and levels of glycemia all associated with higher likelihood of Stage 3 or worse CKD, comparable to findings from surveys from many other areas, which also show micro‐ or macroalbuminuria to be present in one‐sixth to one‐third of diab...
Source: Journal of Diabetes - January 19, 2018 Category: Endocrinology Authors: Zachary Bloomgarden Tags: Editorial Source Type: research
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
This study expands the scope of SGLT-2 inhibitor therapy to prevent cardiovascular disease in diabetic patients beyond those with preexisting cardiovascular disease studied in the previous empagliflozin study, raising the question as to whether SGLT-2 inhibitor therapy should be considered appropriate for most, if not all, type 2 diabetes patients, not only to control hyperglycemia but also to reduce cardiovascular and renal events.
PMID: 29297732 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - January 5, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Cardiovascular outcomes with canagliflozin - is it on the CANVAS?
Authors: Doggrell S
Abstract
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (the 'gliflozins') promote the excretion of glucose from the kidney to lower HbA1c. Empagliflozin was the first gliflozin shown to improve cardiovascular and renal outcomes in subjects with type 2 diabetes and cardiovascular disease. Areas covered: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, there were improvements in the primary cardiovascular and exploratory renal outcomes with canagliflozin, compared to placebo. The safety outcome finding, which was of most interest, was that there was a higher...
Source: Expert Opinion on Pharmacotherapy - December 20, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type2 diabetes mellitus
Persons with type2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a r...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research
SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Persons with type 2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a ...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research
Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research
Letter by Tampaki et al Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk” Letter to the Editor
Source: Stroke - August 28, 2017 Category: Neurology Authors: Ekaterini Christina Tampaki, Athanasios Tampakis, Lorenz Gurke Tags: Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research
Response by Zinman et al to Letter Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk” Letter to the Editor
Source: Stroke - August 28, 2017 Category: Neurology Authors: Bernard Zinman, Silvio E. Inzucchi, Hans Christoph Diener Tags: Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Histo...
Source: Diabetes Care - August 22, 2017 Category: Endocrinology Authors: Marx, N.; McGuire, D. K.; Perkovic, V.; Woerle, H.-J.; Broedl, U. C.; von Eynatten, M.; George, J. T.; Rosenstock, J. Tags: Perspectives in Care Source Type: research
The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Abstract
Introduction Sodium-glucose co-transporters-2inhibitors have emerged as a very promising antidiabetic drug class, with data from the two available cardiovascular trials of this class suggesting remarkable benefits in terms of cardiovascular events, total mortality and renal outcomes. Areas covered Data point toward clinically meaningful benefits from SGLT-2inhibition on a variety of cardiovascular risk factors. Empagliflozin, and to a lesser extent canagliflozin, resulted in significant reductions of an abundance of cardiovascular mortality and morbidity endpoints. SGLT-2inhibitors were also found to redu...
Source: Pharmacological Reviews - August 22, 2017 Category: Drugs & Pharmacology Authors: Imprialos KP, Stavropoulos K, Doumas M, Karagiannis A, Athyros VG Tags: Expert Rev Clin Pharmacol Source Type: research
Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect.
PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research
Update on SGLT2 Inhibitors—New Data Released at the American Diabetes Association
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are one of the newer classes of antiglycemic agents approved for the management of patients with type 2 diabetes mellitus. Due to their unique mechanism of action, SGLT2 inhibitors have shown to be beneficial beyond glucose control. The improvement in cardiovascular (CV) outcomes was first observed in the landmark EMPA-REG OUTCOMES study. Following these results, numerous CV outcome trials were designed to identify whether the beneficial CV and renal effects observed with empagliflozin are unique or a drug class effect. The benefit of SGLT2 inhibition was confirmed by the...
Source: Critical Pathways in Cardiology - July 27, 2017 Category: Cardiology Tags: Review Article Source Type: research
